ReviewDiagnostics (Basel, Switzerland)2020
Invasive Pulmonary Aspergillosis in Patients with SARS-CoV-2 Infection: A Systematic Review of the Literature.
Review in Diagnostics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Mycotic infection as a risk factor for COVID-19: A meta-analysis.Frontiers in public health · 2022Pooled it
- Pooled it
- Decoding CAPA: A Comparative Study of AspICU, ISHAM, and EORTC Criteria in Critical COVID-19 Patients Requiring Mechanical Ventilation.Microorganisms · 2026Article
- Risk and prognostic patterns of viral-associated invasive pulmonary aspergillosis: impact of corticosteroid and antibiotic exposure in non-neutropenic hosts.Journal of thoracic disease · 2025Article
- Invasive Sphenoid Sinus Aspergillosis in a Patient With Chronic Neutropenia: A Case Report.Cureus · 2025Article
- Aspergillosis: A comprehensive review of pathogenesis, drug resistance, and emerging therapeutics.Journal of food and drug analysis · 2025Review
- Fungi identified via next-generation sequencing in bronchoalveolar lavage fluid among patients with COVID-19: a retrospective study.European journal of medical research · 2024Article
- Severe mold fungal infections in critically ill patients with COVID-19.Future microbiology · 2024Review
- Prevalence, Risk Factors, and Mortality of Invasive Pulmonary Aspergillosis in Patients with Anti-MDA5+ Dermatomyositis: A Retrospective Study in China.Journal of inflammation research · 2024Article
- COVID-19 associated mold infections: Review of COVID-19 associated pulmonary aspergillosis and mucormycosis.Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi · 2023Review
- Emerging and re-emerging fungal threats in Africa.Parasite immunology · 2023Review
- COVID-associated pulmonary aspergillosis and herpes simplex virus pneumonia in a renal transplant recipient.Transplant infectious disease : an official journal of the Transplantation Society · 2022Article
- Review
- COVID-19-associated opportunistic infections: a snapshot on the current reports.Clinical and experimental medicine · 2022Review
- Tendency in Pulmonary Aspergillosis Investigation during the COVID-19 Era: What Is Changing?International journal of environmental research and public health · 2022Article
- COVID-19 Pathogenesis and Clinical Manifestations.Infectious disease clinics of North America · 2022Review
- An overview of COVID-19 related to fungal infections: what do we know after the first year of pandemic?Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2022Review
- The Multifaceted Role of Mating Type of the Fungus and Sex of the Host in Studies of Fungal Infections in Humans.Journal of fungi (Basel, Switzerland) · 2022Review
- SARS-CoV-2 Associated Immune Dysregulation and COVID-Associated Pulmonary Aspergilliosis (CAPA): A Cautionary Tale.International journal of molecular sciences · 2022Review
- Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study.Open forum infectious diseases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this systematic review, we investigate the epidemiology, pathogenesis, risk factors, clinical manifestations, diagnosis and treatment of COVID-19-associated pulmonary aspergillosis (CAPA). We identified 85 cases from 22 studies. The frequency of CAPA is currently unknown but ranges between <5% to >30% in different case series; the possibility of colonization rather than invasive disease is the most important confounder. The vast majority of patients with CAPA did not have any of the classic host risk factors, such as immunosuppression from organ transplant or neutropenia, although a significant proportion (46%) had received corticosteroids. Age, pulmonary comorbidities and male sex were associated with higher mortality. Patients treated with voriconazole had numerically lower case-fatality rate. Clinical vigilance for CAPA is advisable in critically ill patients with COVID-19 who are not improving, even those who do not meet classic host criteria for invasive mycoses, especially if they are receiving corticosteroids. A thorough, multi-faceted diagnostic work-up and early initiation of a mold-active triazole may be lifesaving. Further research studies using standardized, uniform definitions of invasive disease and colonization are urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.